KOL Perspectives: Biomarker Potential of Type I IFN Gene Signature in Lupus
This KOL Insight briefing focuses on the IFN gene signature as a potential biomarker in Lupus.
The briefing includes analysis of KOL opinion on the following topic areas-
- Awareness of biomarkers and predictors of disease activity in lupus
- Usefulness of the type I IFN signature test to identify patients who are most likely to respond to IFN-targeting therapies
- Impact of availability of a biomarker on willingness to prescribe a therapy
- Implementing a potential IFN biomarker test in clinical practice
- Willingness to prescribe anifrolumab to patients who do not display the interferon biomarker
- Barriers to using IFN signature test to stratify patients in clinical practice
- Impact of data suggesting that high IFN? gene expression is closely associated with SLE on opinion of anifrolumab's efficacy
- Impact of data suggesting that high IFN? gene expression is more closely associated with LN than IFN? on opinion of anifrolumab's efficacy
- Majority of KOLs use complement & anti-DNA to monitor disease activity in clinical practice, while most are aware of the type I IFN signature test
- Most KOLs flagged that the type I IFN signature test will be useful to stratify patients most likely to respond to type I IFN-targeting therapies
- Most KOLs agreed that the availability of a biomarker would strongly influence their willingness to prescribe a therapy such as anifrolumab.
- The insight briefing is based on Sociable Pharma's analysis of primary research with our lupus key opinion leaders (KOLs)
- In total, we conducted interviews with 14 KOLs: Seven Europe-based & seven US-based
- Interviews performed in December 2017
- KOL data is analyzed to produce: Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts.
Reasons to buy
- Combines Qualitative & semi-quantitative insight from key opinion leaders on "Biomarker Potential of Type I IFN Gene Signature in Lupus"
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Table of Contents
Research Panel Composition
Results & Implications
Single User License:
Corporate User License:
IFN, lupus, anifrolumab, interferon
select a license
NEWSLETTER BY CATEGORY
The report was very informative and gives me an interesting view on the Indian market.... "Area Sales Manager, Muhlen Sohn GmbH & Co. KG"
We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help... "Group Vice President Strategy, Aliaxis"
I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again... "Technical Marketing Manager, Ascendis Health Limited"
I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ... "., Coldwell Banker - Riyadh "
The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future... "International and Business Dev. Director, Duta Abadi Primantara"